Title:
鎌状赤血球症のためのトリアリールメタン化合物
Document Type and Number:
Japanese Patent JP4376970
Kind Code:
B2
Abstract:
The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
More Like This:
| JPH10158182 | URINATION PROMOTER |
| WO/2014/193832 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS |
| JPS52108026 | CHOLAGOGUE |
Inventors:
Bragnara, Carlo
Halperin, jose
Bellotto, Emile M. Jr.
Fraimowitz, mark
Lumberdy, Richard Jay
Clifford, John Jay
Gao, Ing-Duo
Haider, Reem M
Kelleher, Yougene W
Kay, Fargni M
Moussa, Adele M
Sakedev, Yesh Pee
Sun, Mingua
Taft, Heather N
Halperin, jose
Bellotto, Emile M. Jr.
Fraimowitz, mark
Lumberdy, Richard Jay
Clifford, John Jay
Gao, Ing-Duo
Haider, Reem M
Kelleher, Yougene W
Kay, Fargni M
Moussa, Adele M
Sakedev, Yesh Pee
Sun, Mingua
Taft, Heather N
Application Number:
JP53372197A
Publication Date:
December 02, 2009
Filing Date:
March 19, 1997
Export Citation:
Assignee:
President and Fellows of Harvard College
Children's Medical Center Corporation
Nukem Pharmaceuticals Incorporated
Children's Medical Center Corporation
Nukem Pharmaceuticals Incorporated
International Classes:
A61K31/015; C07D295/14; A61K31/02; A61K31/03; A61K31/045; A61K31/05; A61K31/075; A61K31/085; A61K31/10; A61K31/11; A61K31/135; A61K31/14; A61K31/15; A61K31/165; A61K31/19; A61K31/195; A61K31/215; A61K31/275; A61K31/34; A61K31/381; A61K31/40; A61K31/44; A61K31/4453; A61P35/00; A61P43/00; C07C15/16; C07C17/35; C07C22/04; C07C25/18; C07C33/24; C07C33/28; C07C33/34; C07C33/46; C07C39/15; C07C39/367; C07C43/164; C07C43/225; C07C43/23; C07C45/00; C07C45/44; C07C47/23; C07C47/24; C07C47/273; C07C49/163; C07C49/215; C07C49/233; C07C57/38; C07C57/40; C07C57/46; C07C57/58; C07C69/616; C07C69/65; C07C69/76; C07C211/27; C07C211/52; C07C211/54; C07C215/68; C07C217/18; C07C217/20; C07C229/14; C07C233/11; C07C239/20; C07C239/22; C07C255/33; C07C255/35; C07C259/06; C07C321/10; C07D207/08; C07D207/26; C07D213/06; C07D213/16; C07D213/20; C07D213/30; C07D295/145; C07D307/33; C07F7/08; C07F7/10; C07F7/18; C07F7/30; C07F9/535
Other References:
Archiv der Pharmazie,(1991),324(3),p.153-60
Attorney, Agent or Firm:
Kiyoji Kuzuwa